Expression of tumor-associated membrane antigen, RCAS1, in human colorectal carcinomas and possible role in apoptosis of tumor-infiltrating lymphocytes

Modern Pathology

Volumn 16, Issue 7, 2003, Pages 679-685

  Okada, Kazuya ^a   Nakashima, Manabu ^b   Komuta, Ko ^a   Hashimoto, Satoshi ^a   Okudaira, Sadayuki ^a   Baba, Nobuyuki ^a   Hishikawa, Yoshitaka ^a   Koji, Takehiko ^a   Kanematsu, Takashi ^a   Watanabe, Takeshi ^b  

^a NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Apoptosis; Colorectal cancer; Fas; Fas ligand; RCAS1; Tumor infiltrating lymphocytes

Indexed keywords

ANTIGEN RCAS1; MEMBRANE ANTIGEN; PARAFFIN; PEROXIDASE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; BONE MARROW CELL; CANCER SURVIVAL; CELL CULTURE; CELL CYCLE; COLORECTAL CARCINOMA; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; LYMPHOCYTE; LYMPHOID CELL; MAJOR CLINICAL STUDY; MALE; OVARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; UTERUS CARCINOMA;

ADENOCARCINOMA; AGED; ANTIGENS, NEOPLASM; APOPTOSIS; CELL COUNT; COLORECTAL NEOPLASMS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU NICK-END LABELING; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; SURVIVAL RATE;

EID: 10744223788     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.MP.0000074732.17945.6C     Document Type: Article

References (33)

1. Sonoda K, Nakashima M, Kaku T, Kamura T, Nakano H, Watanabe T. A novel tumor-associated antigen expressed in human uterine and ovarian carcinomas. Cancer 1996;77:1501-9.
2. Sonoda K, Kaku T, Kamura T, Nakashima M, Watanabe T, Nakano H. Tumor-associated antigen 22-1-1 expression in the uterine cervical squamous neoplasias. Clin Cancer Res 1998;4:1517-20.
3. Nakashima M, Sonoda K, Watanabe T. Inhibition of cell growth and induction of apoptotic cell death by the human tumor-associated antigen RCAS1. Nat Med 1999;5:938-42.
4. O'Connell J, Bennett MW, O'Sullivan GC, Collins JK, Shanahan F. The Fas counterattack: cancer as a site of immune privilege. Immunol Today 1999;20:46-52.
5. Nagata S. Fas ligand and immune evasion. Nat Med 1996;2:1306-7.
6. Chappell DB, Restifo NP. T cell-tumor cell: a fatal interaction? Cancer Immunol Immunother 1998;47:65-71.
7. Walker PR, Saas P, Dietrich PY. Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back. J Immunol 1997;158:4521-4.
8. Strand S, Galle PR. Immune evasion by tumours: involvement of the CD95 (APO-1/Fas) system and its clinical implications. Mol Med Today 1998;4:63-8.
9. Kubokawa M, Nakashima M, Yao T, Ito K, Harada N, Nawata H, et al. Aberrant intracellular localization of RCAS1 is associated with tumor progression of gastric cancer. Int J Oncol 2001;19:695-700.
10. Noguchi K, Enjoji M, Nakamuta M, Nakashima M, Nishi H, Choi I, et al. Expression of a tumor-associated antigen RCAS1 in hepatocellular carcinoma. Cancer Lett 2001;168:197-202.
11. Kaku T, Sonoda K, Kamura T, Hirakawa T, Sakai K, Amada S, et al. The prognostic significance of tumor-associated antigen 22-1-1 expression in adenocarcinoma of the uterine cervix. Clin Cancer Res 1999;5:1449-53.
12. Izumi M, Nakanishi Y, Yoshino I, Nakashima M, Watanabe T, Hara N. Expression of tumor-associated antigen RCAS1 correlates significantly with poor prognosis in nonsmall cell lung carcinoma. Cancer 2001;92:446-51.
13. Oshikiri T, Hida Y, Miyamoto M, Hashida H, Katoh K, Suzuoki M, et al. RCAS1 as a tumour progression marker: an independent negative prognostic factor in gallbladder cancer. Br J Cancer 2001;85:1922-7.
14. Hiraoka K, Hida Y, Miyamoto M, Oshikiri T, Suzuoki M, Nakakubo Y, et al. High expression of tumor-associated antigen RCAS1 in pancreatic ductal adenocarcinoma is an unfavorable prognostic marker. Int J Cancer 2002;99:418-23.
15. Nakakubo Y, Hida Y, Miyamoto M, Hashida H, Oshikiri T, Kato K, et al. The prognostic significance of RCAS1 expression in squamous cell carcinoma of the oesophagus. Cancer Lett 2002;177:101-5.
16. Koji T. Nonradioactive in situ nick translation: a useful molecular histochemical tool to detect single-stranded DNA breaks. Acta Histochem Cytochem 1996;29:71-9.
17. Hashimoto S, Koji T, Kohara N, Kanematsu T, Nakane PK. Frequency of apoptosis relates inversely to invasiveness and metastatic activity in human colorectal cancer. Virchows Arch 1997;431:241-8.
18. Hashimoto S, Koji T, Niu J, Kanematsu T, Nakane PK. Differential staining of DNA strand breaks in dying cells by non-radioactive in situ nick translation. Arch Histol Cytol 1995;58:161-70.
19. Okada K, Komuta K, Hashimoto S, Matsuzaki S, Kanematsu T, Koji T. Frequency of apoptosis of tumor-infiltrating lymphocytes induced by Fas counterattack in human colorectal carcinoma and its correlation with prognosis. Clin Cancer Res 2000;6:3560-4.
20. Heppner GH. Cell-to-cell interaction in regulating diversity of neoplasms. Semin Cancer Biol 1991;2:97-103.
21. Ropponen KM, Eskelinen MJ, Lipponen PK, Alhava E, Kosma VM. Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer. J Pathol 1997;182:318-24.
22. + T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 1998;58:3491-4.
23. Suda T, Takahashi T, Goldstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993;75:1169-78.
24. Suda T, Nagata S. Purification and characterization of the Fas-ligand that induces apoptosis. J Exp Med 1994;179:873-9.
25. Shukuwa T, Katayama I, Koji T. Fas-mediated apoptosis of melanoma cells and infiltrating lymphocytes in human malignant melanomas. Mod Pathol 2002;15:387-96.
26. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F. The Fas counterattack. Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996;184:1075-82.
27. Hahne M, Rimoldi D, Schroter M, Romero P, Schreier M, French LE, et al. Melanoma cell expression of Fas(Apo-1/ CD95) ligand: implications for tumor immune escape. Science 1996;274:1363-6.
28. Bennett MW, O'Connell J, O'Sullivan GC, Brady C, Roche D, Collins JK, et al. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J Immunol 1998;160:5669-75.
29. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995;3:673-82.
30. Gimmi CD, Morrison BW, Mainprice BA, Gribben JG, Boussiotis VA, Freeman GJ, et al. Breast cancer-associated antigen, DF3/MUC1, induces apoptosis of activated human T cells. Nat Med 1996;2:1367-70.
31. Suzuki T, Inoue S, Kawabata W, Akahira J, Moriya T, Tsuchiya F, et al. EBAG9/RCAS1 in human breast carcinoma: a possible factor in endocrine-immune interactions. Br J Cancer 2001;85:1731-7.
32. Ohshima K, Muta K, Nakashima M, Haraoka S, Tutiya T, Suzumiya J, et al. Expression of human tumor-associated antigen RCAS1 in Reed-Sternberg cells in association with Epstein-Barr virus infection: a potential mechanism of immune evasion. Int J Cancer 2001;93:91-6.
33. Ohshima K, Nakashima M, Sonoda K, Kikuchi M, Watanabe T. Expression of RCAS1 and FasL in human trophoblasts and uterine glands during pregnancy: the possible role in immune privilege. Clin Exp Immunol 2001;123:481-6.